Metabolic reprogramming and its clinical application in thyroid cancer (Review)

Shi Shuai Wen, Ting Ting Zhang, Di Xin Xue, Wei Li Wu, Yu Long Wang, Yu Wang, Qing Hai Ji, Yong Xue Zhu, Ning Qu, Rong Liang Shi

Research output: Contribution to journalReview article

Abstract

Warburg found that tumor cells exhibit high-level glycolysis, even under aerobic condition, which is known as the ‘Warburg effect’. As systemic changes in the entire metabolic network are gradually revealed, it is recognized that metabolic reprogramming has gone far beyond the imagination of Warburg. Metabolic reprogramming involves an active change in cancer cells to adapt to their biological characteristics. Thyroid cancer is a common endocrine malignant tumor whose metabolic characteristics have been studied in recent years. Some drugs targeting tumor metabolism are under clinical trial. This article reviews the metabolic changes and mechanisms in thyroid cancer, aiming to find metabolic-related molecules that could be potential markers to predict prognosis and metabolic pathways, or could serve as therapeutic targets. Our review indicates that knowledge in metabolic alteration has potential contributions in the diagnosis, treatment and prognostic evaluation of thyroid cancer, but further studies are needed for verification as well.

Original languageEnglish (US)
Pages (from-to)1579-1584
Number of pages6
JournalOncology Letters
Volume18
Issue number2
DOIs
StatePublished - Aug 2019

Fingerprint

Thyroid Neoplasms
Metabolic Networks and Pathways
Neoplasms
Imagination
Glycolysis
Drug Delivery Systems
Clinical Trials
Therapeutics

Keywords

  • Metabolism
  • Predictive factor
  • Prognosis
  • Targeted therapy
  • Thyroid cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wen, S. S., Zhang, T. T., Xue, D. X., Wu, W. L., Wang, Y. L., Wang, Y., ... Shi, R. L. (2019). Metabolic reprogramming and its clinical application in thyroid cancer (Review). Oncology Letters, 18(2), 1579-1584. https://doi.org/10.3892/ol.2019.10485

Metabolic reprogramming and its clinical application in thyroid cancer (Review). / Wen, Shi Shuai; Zhang, Ting Ting; Xue, Di Xin; Wu, Wei Li; Wang, Yu Long; Wang, Yu; Ji, Qing Hai; Zhu, Yong Xue; Qu, Ning; Shi, Rong Liang.

In: Oncology Letters, Vol. 18, No. 2, 08.2019, p. 1579-1584.

Research output: Contribution to journalReview article

Wen, SS, Zhang, TT, Xue, DX, Wu, WL, Wang, YL, Wang, Y, Ji, QH, Zhu, YX, Qu, N & Shi, RL 2019, 'Metabolic reprogramming and its clinical application in thyroid cancer (Review)', Oncology Letters, vol. 18, no. 2, pp. 1579-1584. https://doi.org/10.3892/ol.2019.10485
Wen, Shi Shuai ; Zhang, Ting Ting ; Xue, Di Xin ; Wu, Wei Li ; Wang, Yu Long ; Wang, Yu ; Ji, Qing Hai ; Zhu, Yong Xue ; Qu, Ning ; Shi, Rong Liang. / Metabolic reprogramming and its clinical application in thyroid cancer (Review). In: Oncology Letters. 2019 ; Vol. 18, No. 2. pp. 1579-1584.
@article{2059da5344df461cb917164c98dafdbe,
title = "Metabolic reprogramming and its clinical application in thyroid cancer (Review)",
abstract = "Warburg found that tumor cells exhibit high-level glycolysis, even under aerobic condition, which is known as the ‘Warburg effect’. As systemic changes in the entire metabolic network are gradually revealed, it is recognized that metabolic reprogramming has gone far beyond the imagination of Warburg. Metabolic reprogramming involves an active change in cancer cells to adapt to their biological characteristics. Thyroid cancer is a common endocrine malignant tumor whose metabolic characteristics have been studied in recent years. Some drugs targeting tumor metabolism are under clinical trial. This article reviews the metabolic changes and mechanisms in thyroid cancer, aiming to find metabolic-related molecules that could be potential markers to predict prognosis and metabolic pathways, or could serve as therapeutic targets. Our review indicates that knowledge in metabolic alteration has potential contributions in the diagnosis, treatment and prognostic evaluation of thyroid cancer, but further studies are needed for verification as well.",
keywords = "Metabolism, Predictive factor, Prognosis, Targeted therapy, Thyroid cancer",
author = "Wen, {Shi Shuai} and Zhang, {Ting Ting} and Xue, {Di Xin} and Wu, {Wei Li} and Wang, {Yu Long} and Yu Wang and Ji, {Qing Hai} and Zhu, {Yong Xue} and Ning Qu and Shi, {Rong Liang}",
year = "2019",
month = "8",
doi = "10.3892/ol.2019.10485",
language = "English (US)",
volume = "18",
pages = "1579--1584",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Metabolic reprogramming and its clinical application in thyroid cancer (Review)

AU - Wen, Shi Shuai

AU - Zhang, Ting Ting

AU - Xue, Di Xin

AU - Wu, Wei Li

AU - Wang, Yu Long

AU - Wang, Yu

AU - Ji, Qing Hai

AU - Zhu, Yong Xue

AU - Qu, Ning

AU - Shi, Rong Liang

PY - 2019/8

Y1 - 2019/8

N2 - Warburg found that tumor cells exhibit high-level glycolysis, even under aerobic condition, which is known as the ‘Warburg effect’. As systemic changes in the entire metabolic network are gradually revealed, it is recognized that metabolic reprogramming has gone far beyond the imagination of Warburg. Metabolic reprogramming involves an active change in cancer cells to adapt to their biological characteristics. Thyroid cancer is a common endocrine malignant tumor whose metabolic characteristics have been studied in recent years. Some drugs targeting tumor metabolism are under clinical trial. This article reviews the metabolic changes and mechanisms in thyroid cancer, aiming to find metabolic-related molecules that could be potential markers to predict prognosis and metabolic pathways, or could serve as therapeutic targets. Our review indicates that knowledge in metabolic alteration has potential contributions in the diagnosis, treatment and prognostic evaluation of thyroid cancer, but further studies are needed for verification as well.

AB - Warburg found that tumor cells exhibit high-level glycolysis, even under aerobic condition, which is known as the ‘Warburg effect’. As systemic changes in the entire metabolic network are gradually revealed, it is recognized that metabolic reprogramming has gone far beyond the imagination of Warburg. Metabolic reprogramming involves an active change in cancer cells to adapt to their biological characteristics. Thyroid cancer is a common endocrine malignant tumor whose metabolic characteristics have been studied in recent years. Some drugs targeting tumor metabolism are under clinical trial. This article reviews the metabolic changes and mechanisms in thyroid cancer, aiming to find metabolic-related molecules that could be potential markers to predict prognosis and metabolic pathways, or could serve as therapeutic targets. Our review indicates that knowledge in metabolic alteration has potential contributions in the diagnosis, treatment and prognostic evaluation of thyroid cancer, but further studies are needed for verification as well.

KW - Metabolism

KW - Predictive factor

KW - Prognosis

KW - Targeted therapy

KW - Thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=85069911591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069911591&partnerID=8YFLogxK

U2 - 10.3892/ol.2019.10485

DO - 10.3892/ol.2019.10485

M3 - Review article

AN - SCOPUS:85069911591

VL - 18

SP - 1579

EP - 1584

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 2

ER -